bs-0784R **[Primary Antibody]**

IFNB1 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

Target: IFNB1

Immunogen: KLH conjugated synthetic peptide derived from mouse IFNB1: 101-184/184.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a cytokine that belongs to the interferon family of signaling proteins, which are released as part of the innate immune response to pathogens. The protein encoded by this gene belongs to the type I class of interferons, which are important for defense against viral infections. In addition, type I interferons are involved in cell differentiation and anti-tumor defenses. Following secretion in response to a pathogen, type I interferons bind a homologous receptor complex and induce transcription of genes such as those encoding inflammatory cytokines and chemokines. Overactivation of type I interferon secretion is linked to autoimmune diseases. Mice deficient for this gene display several phenotypes including defects in B cell maturation and increased susceptibility to viral infection. [provided by RefSeq, Sep 2015]

Applications: **WB** (1:500-2000)

Reactivity: Human, Mouse (predicted: Rat)

Predicted MW.: 20 kDa

Subcellular Location: Secreted

VALIDATION IMAGES



Sample: Lane 1: Raw264.7 (Mouse) Cell Lysate at 30 ug Lane 2: THP-1 (Human) Cell Lysate at 30 ug Primary: Anti-IFN beta (bs-0784R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 24 kD Observed band size: 24 kD

SELECTED CITATIONS

- **[IF=19]** Bingchen Zhang. et al. Precise RNA Editing: Cascade Self-Uncloaking Dual-Prodrug Nanoassemblies Based on CRISPR/Cas13a for Pleiotropic Immunotherapy of PD-L1-Resistant Colorectal Cancer. ADV FUNCT MATER. 2023 Sep;:2305630 WB ;Mouse. 10.1002/adfm.202305630
- **[IF=15.8]** Loretah Chibaya. et al. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. SCI TRANSL MED. 2024 Aug;16(762) IF ;Mouse. 39196958
- **[IF=14.588]** Hou L et al. Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity. ACS Nano. 2020 Apr 28;14(4):3927-3940. Other ;. 3229807
- **[IF=13.273]** Weihong Guo. et al. Improved immunotherapy for gastric cancer by nanocomposites with capability of

triggering Dual-Damage of Nuclear/Mitochondrial DNA and cGAS/STING-Mediated innate immunity. CHEM ENG J. 2022 Sep;443:136428 WB ;Mouse. 10.1016/j.cej.2022.136428

- **[IF=13.2]** Nier Wu. et al. DNA nanotube-carrying antimicrobial peptide confers improved anti-infective therapy. NANO TODAY. 2024 Dec;59:102508 IHC ;Mouse. 10.1016/j.nantod.2024.102508